title: Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
abstract: BACKGROUND
  Nefazodone hydrochloride, an antidepressant that acts as a 5-HT2 antagonist and serotonin (5-HT) and norepinephrine uptake inhibitor, was evaluated in a double-blind, imipramine- and placebo-controlled study involving 128 patients with major depression.
  
  
  METHODS
  Eligible patients were randomly assigned to receive placebo (2 to 6 capsules/day), imipramine (100 to 300 mg/day), or nefazodone (200 to 600 mg/day) for 8 weeks. The principal efficacy outcome measure assessed was the number of patients who experienced an adequate response during treatment.
  
  
  RESULTS
  Based on global improvement (Clinical Global Impressions-Improvement), 67% of nefazodone-treated patients (p < or = .01) and 63% of imipramine-treated patients (p < or = .05) responded during 8 weeks of treatment, compared with 36% of placebo controls. Sixty-two percent of nefazodone-treated, 53% of imipramine-treated, and 26% of placebo-treated patients had 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores < or = 10 on completion of acute treatment. Nefazodone-treated patients had a lower incidence of premature treatment discontinuation and fewer dropouts for adverse events than the imipramine group.
  
  
  CONCLUSIONS
  In a three arm comparison with imipramine and placebo, nefazodone had the greatest number of patients with major depression who responded to therapy. Nefazodone, a new antidepressant with novel pharmacology, is a well-tolerated, efficacious antidepressant.
authors.affiliation: Cohn Center, Houston, Tex, USA.
authors.forename: C K
authors.initials: CK
authors.lastname: Cohn
authors.forename: D S
authors.initials: DS
authors.lastname: Robinson
authors.forename: D L
authors.initials: DL
authors.lastname: Roberts
authors.forename: U E
authors.initials: UE
authors.lastname: Schwiderski
authors.forename: K
authors.initials: K
authors.lastname: O'Brien
authors.forename: J R
authors.initials: JR
authors.lastname: Ieni
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D010555:Personality Inventory; D010879:Piperazines; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D010919:Placebos; D014230:Triazoles; C051752:nefazodone; D007099:Imipramine